MiMedx Group Past Earnings Performance

Past criteria checks 5/6

MiMedx Group has been growing earnings at an average annual rate of 57.6%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 3.6% per year. MiMedx Group's return on equity is 47.4%, and it has net margins of 23.2%.

Key information

57.6%

Earnings growth rate

56.0%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate3.6%
Return on equity47.4%
Net Margin23.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease

Dec 23
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease

We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease

Nov 21
We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease

There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise

Nov 06
There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

May 21
MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

May 14
We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Mar 27
Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Jan 05
We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 18
MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

Aug 08
Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Apr 22
Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

Dec 20
Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX

Sep 12

MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range

Sep 06

Revenue & Expenses Breakdown

How MiMedx Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:MDXG Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243437921011
30 Jun 243407920911
31 Mar 243356821612
31 Dec 233215621613
30 Sep 23309192156
30 Jun 2329522198
31 Mar 23281-1822510
31 Dec 22268-2722113
30 Sep 22261-3421622
30 Jun 22256-2820920
31 Mar 22258-1920219
31 Dec 21242-1819910
30 Sep 21260-3522316
30 Jun 21261-8323315
31 Mar 21246-8823113
31 Dec 20248-8324012
30 Sep 20256-7321211
30 Jun 20281-821010
31 Mar 20294-1723311
31 Dec 19299-2626511
30 Sep 19315-5427013
30 Jun 19314-6728714
31 Mar 19342-4829515
31 Dec 18359-3029516
30 Sep 183544127515
30 Jun 183525926016
31 Mar 183336523517
31 Dec 173216522018
30 Sep 173033521618
30 Jun 172832120515
31 Mar 172641519214
31 Dec 16222017214
30 Sep 162272016811
30 Jun 162122315410
31 Mar 16200271449
31 Dec 15187291338
30 Sep 15175201268
30 Jun 15160171158
31 Mar 15139111047
31 Dec 141186907
30 Sep 14971757
30 Jun 1479-3646
31 Mar 1467-3545

Quality Earnings: MDXG has a high level of non-cash earnings.

Growing Profit Margin: MDXG's current net profit margins (23.2%) are higher than last year (6.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MDXG has become profitable over the past 5 years, growing earnings by 57.6% per year.

Accelerating Growth: MDXG's earnings growth over the past year (315.6%) exceeds its 5-year average (57.6% per year).

Earnings vs Industry: MDXG earnings growth over the past year (315.6%) exceeded the Biotechs industry 20%.


Return on Equity

High ROE: MDXG's Return on Equity (47.4%) is considered outstanding.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 03:23
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MiMedx Group, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason WittesBrean Capital
William PlovanicCanaccord Genuity
Ross OsbornCantor Fitzgerald & Co.